Study summary · research use only
Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This study used 3 x Tg-AD transgenic mice, a mouse model of Alzheimer's disease, and wild-type mice to test Peptide 021 (P021), a neurotrophic/neurogenic tetra-peptide derived from the ciliary neurotrophic factor (CNTF) active region with admantylated glycine added to its C-terminal. P021 was administered in the diet starting at 3 months of age, before overt amyloid beta or tau pathology, and continued until 21 months in 3 x Tg-AD mice; 3 x Tg-AD and wild-type mice otherwise received a vehicle-only diet as controls. The authors measured effects on neurogenesis, dendritic and synaptic markers, and cognitive performance, and report that P021 treatment was associated with rescued dendritic and synaptic deficits, increased neurogenesis, and reversed cognitive impairment in the 3 x Tg-AD mice.
Abstract
The use of neurotrophic factors to treat Alzheimer's disease (AD) is hindered by their blood-brain barrier impermeability, short half-life, and severe side effects. Peptide 021 (P021) is a neurotrophic/neurogenic tetra-peptide that was derived from the most active region of the ciliary neurotrophic factor (CNTF) by epitope mapping. Admantylated glycine was added to its C-terminal to increase its blood-brain barrier permeability and decrease its degradation by exopeptidases to make it druggable. Here, we report on the preventive effect of P021 in 3 × Tg-AD, a transgenic mouse model of AD. P021 was administered in the diet at 3 months, i.e., 6-9 months before any overt amyloid beta (Aβ) or tau pathology, and during the period of synaptic compensation, and was continued until 21 months in 3 × Tg-AD mice. The 3 × Tg-AD mice and wild-type (WT) mice were treated identically but with a vehicle-only diet serving as controls. The effects of P021 on neurogenesis, dendritic and synaptic markers, and cognitive performance were investigated. We found that P021 treatment was able to rescue dendritic and synaptic deficits, boost neurogenesis, and reverse cognitive impairment in 3 × Tg-AD mice. Availability of appropriate neurotrophic support during the period of synaptic compensation can prevent synaptic deficit and cognitive impairment, and P021 is a promising neurotrophic compound for this purpose.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.